Table 1.
Clinical and therapeutic characteristics of the DLB-hallu and the DLB-c groups ( N = 66) a
| DLB-hallu ( n = 36) | DLB-c ( n = 30) | P -value | ||
|---|---|---|---|---|
| Mean age, yr (SD) | 71.7 (10.2) | 73.5 (6.9) | 0.41 | |
| Sex (M/F) | 19/14 | 18/10 | 0.89 | |
| Mean MMSE score (SD) | 21.7 (5.6) | 23.3 (4.3) | 0.20 | |
| Extrapyramidal syndrome (scoreb) | ||||
| Akinesia (0/1/2/3/4) | 3/18/11/4/0 | 4/19/5/2/0 | 0.12 | |
| Rigidity (0/1/2/3/4) | 4/25/5/2/0 | 5/15/7/3/0 | 0.469 | |
| Tremor at rest (0/1/2/3/4) | 29/7/0/0/0 | 22/7/0/0/0 | 0.733 | |
| Fluctuations | 32 | 21 | 0.07 | |
| History of depression | 13 | 12 | 0.74 | |
| Delirium episode | 7 | 5 | 0.77 | |
| Sleep disturbance | 12 | 9 | 0.74 | |
| Neuroleptics | 13 | 2 | 0.006 | |
| Dopaminergic medication | 4 | 8 | 0.10 | |
| AChEI | 16 | 9 | 0.22 | |
aAChEI, Acetylcholinesterase inhibitor; DLB-c, Control group of patients with dementia with Lewy bodies who were not having visual hallucinations; DLB-hallu, Study group of patients with dementia with Lewy bodies who were having visual hallucinations; MMSE: Mini Mental State Examination; SD, Standard. Data are number of patients, unless otherwise indicated.